Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report sent to investors on Monday morning,RTT News reports. Wedbush currently has a $11.00 price target on the stock.

A number of other equities analysts have also recently issued reports on the stock. Oppenheimer cut their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Royal Bank of Canada cut their price target on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday, November 25th. Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective for the company. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Finally, UBS Group started coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.14.

Perspective Therapeutics Price Performance

CATX stock opened at $3.40 on Monday. The stock’s 50 day simple moving average is $4.98 and its 200 day simple moving average is $10.20. Perspective Therapeutics has a 12-month low of $2.70 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The company had revenue of $0.37 million for the quarter. On average, sell-side analysts forecast that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Activity

In other news, CFO Jonathan Robert Hunt purchased 12,829 shares of the stock in a transaction dated Monday, November 25th. The shares were bought at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the transaction, the chief financial officer now owns 48,800 shares in the company, valued at $186,416. This trade represents a 35.66 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Heidi Henson acquired 25,975 shares of the company’s stock in a transaction dated Wednesday, December 4th. The stock was purchased at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 67,570 shares of company stock valued at $256,789. Company insiders own 3.52% of the company’s stock.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its holdings in shares of Perspective Therapeutics by 24.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,912 shares of the company’s stock worth $333,000 after purchasing an additional 4,844 shares in the last quarter. Barclays PLC grew its position in Perspective Therapeutics by 587.9% in the third quarter. Barclays PLC now owns 114,075 shares of the company’s stock worth $1,523,000 after buying an additional 97,493 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Perspective Therapeutics by 12.5% in the third quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock valued at $15,546,000 after buying an additional 129,654 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Perspective Therapeutics during the 3rd quarter valued at $498,000. Finally, State Street Corp boosted its stake in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares in the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.